In the E.U., secukinumab is edging closer to approval for use in pediatric patients with juvenile idiopathic arthritis (JIA), specifically those with enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (PsA). In May, the Committee for Medicinal Products for Human Use of the European Medicines Agency issued a positive opinion on expanding its indications.
![](https://www.the-rheumatologist.org/wp-content/uploads/2017/07/NestorRizhniak_Shutterstock_GenericChild_500x270-150x150.jpg)